The rising SARS‐CoV‐2 JN. 1 variant: evolution, infectivity, immune escape, and response strategies
Y Lu, D Ao, X He, X Wei - MedComm, 2024 - Wiley Online Library
The JN. 1 variant of COVID‐19 has emerged as the dominant strain worldwide since the end
of 2023. As a subclade of the BA. 2.86 variant, JN. 1 harbors a unique combination of …
of 2023. As a subclade of the BA. 2.86 variant, JN. 1 harbors a unique combination of …
[HTML][HTML] Advances and Challenges in Antiviral Development for Respiratory Viruses
LA De Jesús-González, M León-Juárez… - Pathogens, 2024 - mdpi.com
The development of antivirals for respiratory viruses has advanced markedly in response to
the growing threat of pathogens such as Influenzavirus (IAV), respiratory syncytial virus …
the growing threat of pathogens such as Influenzavirus (IAV), respiratory syncytial virus …
[HTML][HTML] Study of Potential Blocking Peptides Targeting the SARS-CoV-2 RBD/hACE2 Interaction
SM Villada-Troncoso, JA Arévalo-Romero… - Pharmaceuticals, 2024 - mdpi.com
Background/Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the causative agent of COVID-19, was declared a public health emergency in early 2020 …
the causative agent of COVID-19, was declared a public health emergency in early 2020 …
[HTML][HTML] In Silico Design of miniACE2 Decoys with In Vitro Enhanced Neutralization Activity against SARS-CoV-2, Encompassing Omicron Subvariants
JA Arévalo-Romero, G López-Cantillo… - International journal of …, 2024 - mdpi.com
The COVID-19 pandemic has overwhelmed healthcare systems and triggered global
economic downturns. While vaccines have reduced the lethality rate of SARS-CoV-2 to 0.9 …
economic downturns. While vaccines have reduced the lethality rate of SARS-CoV-2 to 0.9 …
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant
P Parua, S Ghosh, K Jana, A Seth… - Current …, 2024 - benthamdirect.com
Background The COVID-19 pandemic has spurred significant endeavors to devise
treatments to combat SARS-CoV-2. A limited array of small-molecule antiviral drugs …
treatments to combat SARS-CoV-2. A limited array of small-molecule antiviral drugs …
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2
Understanding the antibody response to SARS-CoV-2, the virus responsible for COVID-19,
is crucial to comprehending disease progression and the significance of vaccine and …
is crucial to comprehending disease progression and the significance of vaccine and …
Immunoinformatics-Based Design of Broad-Spectrum Multi-Epitope Vaccines Targeting Mutations in Emerging SARS-CoV-2 Variants
X Mei, W Xie, X Lin, L Zhu, J Li - 2024 - researchsquare.com
The ongoing COVID-19 pandemic, intensified by emerging SARS-CoV-2 mutations,
highlights the urgent need for enhanced vaccines. Despite considerable efforts in vaccine …
highlights the urgent need for enhanced vaccines. Despite considerable efforts in vaccine …